Results 221 to 230 of about 361,016 (249)

Targeting DESI2 as a Novel Therapeutic Strategy for JAK2‐Mutant Leukemias

Advanced Science, EarlyView.
Mass spectrometry‐based proteomics identify DESI2 as a novel component of the JAK2‐V617F complex, which associates with and stabilizes mutant JAK2 through deSUMOylation and deubiquitination, therefore promoting JAK2 mutant cell growth and MPN disease onset in vivo.
Husheng Mei, Wuqiang Wen, Wenjun Zhang, Shujing Zhang, Ting Sun, Guiming Li, Jing Zhang, Shuang Qi, Jie Zhou, Bing Li, Yunshuo Zhao, Xiaotong Chen, Bowen Li, Yiying Xue, Wang Lu, Yanli Sun, Jingyao Wang, Hengyue Shan, Shengzhe Zhang, Yushan Huang, Yisa Chen, Wenchao Wang, Qingsong Liu, Wenchao Lu, Li Tan, Yi Ding, Jianfei Fu, Jun Long, Lei Zhang, Baobing Zhao, Aibin Liang, Baishan Jiang, Jing Yang   +32 more
wiley   +1 more source

Albumin Levels Are Predictive of Cachexia-Induced Time-Dependent Clearance of Therapeutic Antibodies: A Physiologically Based Pharmacokinetic Model of Durvalumab. [PDF]

CPT Pharmacometrics Syst Pharmacol
Proctor JR, Wong H.
europepmc   +1 more source

Targeting Microglial CD49a Inhibits Neuroinflammation and Demonstrates Therapeutic Potential for Parkinson's Disease

Advanced Science, EarlyView.
This study shows that integrin receptor CD49a (Itga1 gene) is significantly upregulated in hyperactivated microglia and microglia‐specific knockdown of Itga1 rescues neuroinflammation and neurodegeneration in a chronic Parkinson's disease (PD) model by targeting PGAM5‐mediated mitochondrial dysfunction and NLRP3 activation. Targeted inhibition of CD49a
Huanpeng Lu, Yunmin Zhu, Xi Wang, Zelin Wu, Zijian Xu, Rongqing Chen, Yanwu Guo   +6 more
wiley   +1 more source

Safety, Tolerability, and Pharmacokinetics of a Novel Nitroimidazooxazole Antitubercular Agent in Healthy Adults: A Phase I Trial. [PDF]

MedComm (2020)
Miao J, Wang Z, Ding Z, Shi H, Qin Y, Gao T, Jiang N, He J, Wang M, Wei X.   +9 more
europepmc   +1 more source

The Association Between Genetic Polymorphisms of <i>UGT1A1</i>, <i>ABCG2</i>, and <i>NR1I2</i> and Dolutegravir Pharmacokinetic Parameters in Thai People Living with HIV. [PDF]

Pharmaceutics
Chanruang A, Birnbaum AK, Sirilun S, Chupradit S, Ubolyam S, Hiranburana N, Cho YS, Shin JG, Avihingsanon A, Punyawudho B.   +9 more
europepmc   +1 more source